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Abstract
Treatment modalities for small renal masses (SRMs) include open or minimally invasive radical or partial nephrectomy, and
laparoscopic or percutaneous ablations. Members of the Endourological Society were surveyed to evaluate how practitioner
and clinical practice characteristics may be associated with the management of SRMs over time. The survey assessed character-
istics of urologists (recency of residency and fellowship training, clinical practice type and location, and treatment modalities
available) and their management of SRMs over the past year and over the course of the year 5 years prior. Of the 1495 surveys
e-mailed, there were 129 respondents (8.6%). Comparing the past year to 5 years prior, there was increasing utilization of robotic
partial nephrectomy (p < 0.001) and robotic radial nephrectomy (p = 0.031). In contrast, there was decreasing utilization of
open partial nephrectomy (p < 0.001), open radical nephrectomy (p = 0.039), laparoscopic partial nephrectomy (p = 0.002),
and laparoscopic radical nephrectomy (p = 0.041). Employment of laparoscopic ablation decreased (p = 0.001), but that of per-
cutaneous ablation did not change signiﬁcantly. For masses treated with image-guided therapy, there was increasing utilization
of microwave ablation (p = 0.008) and decreasing usage of radiofrequency ablation (p = 0.002). Future studies should focus on the
most effective treatment modalities based on provider, patient, and tumor characteristics.
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Introduction
With increased utilization of CT scans, ultrasound, and other
diagnostic imaging techniques, the incidental detection of
renal masses has become progressively more common (1–5).
Commensurate with this trend, the incidence of small renal
masses (SRMs) has steadily grown by as much as 3.7% annually
since the 1970s (2, 6, 7). As evidenced by the American Urolo-
gical Association (AUA) guidelines, numerous options exist for
the management of SRMs. These include open or minimally
invasive radical or partial nephrectomy, percutaneous cryo-,
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microwave, or radiofrequency ablation, and active surveil-
lance (8). However, many of these treatment options involve
newer technologies and have only recently become more
widely utilized. For instance, in 1998, urologists performed
a radical nephrectomy for 58% of cortical renal masses up
to 2 cm and 76% between 2 and 4 cm. Over the next decade,
these numbers gradually declined to 29% and 48%, respec-
tively. Correspondingly, the employment of partial nephrect-
omy, ablation, and active surveillance has increased (9).
Despite an increase in partial nephrectomy over time, recent
literature suggests that partial nephrectomy is still underuti-
lized (10–13). Although changes in management of SRMs
have been previously described, factors which may relate to
current practice patterns have not yet been illustrated. This
study sought to describe the clinical, surgical, geographic
and temporal factors that may relate to management strate-
gies by members of the Endourological Society who practice
in the United States.
Materials and methods
Survey administration and audience
An electronic survey was designed to assess the characteristics
of urologists, their clinical practices, and their management
of SRMs both in the past year and during the year 5 years
prior. The survey can be viewed in Supplementary File 1. Insti-
tutional Review Board approval was obtained. The survey was
administered through the Washington University School of
Medicine Research Electronic Data Capture (REDCap) sys-
tem. It was distributed to all members of the Endourological
Society with a registered e-mail address and residence within
the United States as listed on the Endourological Society web-
site (www.endourology.org). A unique URL ensured that each
receipient could only respond once. A follow-up e-mail was
sent after 2 weeks to those who had not responded. Individuals
who appeared to be industry representatives based on the
domain of their e-mail addresses were excluded.
Statistical analyses
McNemar’s chi-square test compared availability of each
modality in the past year and 5 years prior. Chi-square test
of independence and Fisher’s exact test compared utilization
rates of each modality in the past year and 5 years prior for
the entire data set and subgrouped by practice and practi-
tioner characteristics. Statistical signiﬁcance was determined
to be p < 0.05. All statistical analyses were performed using
R v3.3.1 (14).
Results
Supplementary data
Supplementary data of this article, as supplied by the authors,
are available as pdf on the journal’s website. They can be
accessed via the following link: http://jkcvhl.com/index.php/
jkcvhl/rt/suppFiles/82/0.
Respondent characteristics
Of the 1495 surveys e-mailed, 450 were undeliverable. There
were 129 respondents in total (8.6%). Demographics regarding
the respondents and their practices are detailed in Table 1.
Most respondents had completed a fellowship (70%), the
most popular of which was endourology (53/129, 41%).
Approximately half of the fellowship-trained respondents
(44/87, 50.6%) completed fellowship in the past 5 years.
Regarding the number of clinic patients seen per week, the
most common response was 50–75 (44/129, 34.1%).
Treatment modalities for SRMs
Data regarding treatment modalities employed by the entire
cohort are available in Table 2. All treatment modalities
except robotic surgery had similar availability to urologists
in the past year compared to 5 years prior. Robotic surgery
was more commonly available in the last year (96% vs.
83.5%, p = 0.002). Table 3 details the rates of usage for various
SRM treatment modalities. Comparing 5 years prior with the
past year, there was increasing utilization of robotic partial
nephrectomy (p < 0.001) and robotic radical nephrectomy
(p = 0.031). In contrast, there was decreasing utilization of
open partial nephrectomy (p < 0.001), open radical nephrect-
omy (p = 0.039), laparoscopic partial nephrectomy (p =
0.002), laparoscopic radical nephrectomy (p = 0.041), and
laparoscopic ablation (p = 0.001). Of the renal masses treated
with image-guided therapy, the survey data showed decreased
usage of radiofrequency ablation (p = 0.002) and increased
usage of microwave ablation (p = 0.008) in the past year com-
pared to 5 years prior. Table 4 provides an abridged summary
of respondent practice patterns during the two time periods.
By practice type
Subgrouping the data by practice type (academic, nonaca-
demic hospital-based, and private practice), there were no
signiﬁcant differences in the employment of the various
treatment modalities in the past year. Five years ago, the
usage of robotic radical nephrectomy differed among the
practice types (p = 0.043); academic, private practice, and
nonacademic hospital-based urologists reported utilization
rates of 11.6%, 15%, and 0%, respectively, for ≥25% of
SRM cases. There were no signiﬁcant differences when com-
paring changes in utilization over time for the different
practice types (Supplementary Table 1).
By practice setting
There were no signiﬁcant differences in the utilization of
treatment modalities based on practice setting (metropolitan
and nonmetropolitan) in either time period. Of the respon-
dents who utilized ablation, nonmetropolitan urologists
Trends in the management of small renal masses
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Table 1. Summary of respondent training and practice characteristics
Variable Respondents (%) (N = 129)
Resident time frame
0–5 years ago 56 (43.4)
6–10 years ago 28 (21.7)
11–15 years ago 20 (15.5)
>15 years ago 25 (19.4)
Fellowship training
Endourology 53 (41.1)
Robotics 5 (3.9)
Reconstructive 4 (3.1)
Oncology 22 (17.1)
Transplant 1 (0.8)
Female urology 2 (1.6)
Infertility 0 (0.0)
Pediatrics 4 (3.1)
Research 5 (3.9)
Other 1 (0.8)
No fellowship 39 (30.2)
Fellowship time frame
0–5 years ago 44 (50.6)
6–10 years ago 16 (18.4)
11–15 years ago 14 (16.1)
>15 years ago 13 (14.9)
Region
West 24 (18.6)
Midwest 34 (26.4)
Northeast/New England 36 (27.9)
South 33 (25.6)
Other 2 (1.6)
Practice type
Academic 63 (49.2)
Nonacademic, hospital based 23 (18.0)
Private practice 42 (32.8)
Practice setting
Metropolitan 103 (80.5)
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increased usage of radiofrequency ablation (p = 0.04) and
decreased usage of cryoablation (p = 0.05) at greater rates
over the past 5 years compared to metropolitan urologists
(Supplementary Table 2).
By fellowship training
Completed data and statistical analyses pertaining to treat-
ment modality in relation to fellowship training versus no
fellowship training can be found in Supplementary Table 3.
Data separated by fellowship type are included in Supple-
mentary Table 4a and 4b. Respondents who had completed
a fellowship more often performed open partial nephrect-
omy in the last year than those without fellowship training
(p = 0.029). Further, urologists who completed an endourology
fellowship or no fellowship performed open partial nephrect-
omy and open radical nephrectomy less than urologists who
completed an oncology or other fellowships (p = 0.001 and
0.025, respectively). Members of the Endourological Society
who completed an endourology fellowships trended toward
greater utilization of robotic partial nephrectomy in the past
year when compared to urologists with other training back-
grounds (when comparing utilization with greater than
75% of SRMs to utilization with less than 75% of SRMs),
although this relationship did not reach statistical signiﬁcance
(p = 0.064). Of urologists who utilized image-guided therapy,
fellowship-trained urologists were less likely to use cryoabla-
tion and more likely to use microwave ablation compared to
non-fellowship-trained urologists in the past year (p = 0.028
and 0.018, respectively). In addition, of those who performed
ablation procedures, 35.7% of endourology-trained urologists
increased their implementation of microwave ablation over
the past 5 years compared to 0% for other fellowship-trained
and non-fellowship-trained urologists (p = 0.001).
Table 1. (Continued )
Variable Respondents (%) (N = 129)
Nonmetropolitan 25 (19.5)
Number of patients per week
<50 27 (20.9)
50–75 44 (34.1)
76–100 36 (27.9)
101–125 16 (12.4)
126–150 5 (3.9)
>150 1 (0.8)
Percentage of patients with BMI > 30
<10 3 (2.3)
10–25 17 (13.3)
25–50 67 (52.3)
50–75 39 (29.7)
75–100 3 (2.3)
BMI, body mass index.
Table 2. Availability of treatment modalities for SRMs within the past year and 5 years ago
Available modality
Within the past
yearRespondents (%)
(N = 124)
Five years agoRespondents
(%) (N = 85)
p
Robotic surgery 119 (96.0) 71 (83.5) 0.002
Laparoscopic surgery 119 (96.0) 82 (96.5) 0.852
Percutaneous ablation 113 (91.1) 75 (88.2) 0.494
Laparoscopic ablation 98 (79.0) 70 (82.4) 0.553
All available 92 (74.2) 56 (65.9) 0.194
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Table 3. Usage rates of treatment modalities for SRMs within the past year and 5 years ago
Usage rate per modality
Within the past year
Percentage of respondents
(N = 124)
Five years ago
Percentage of respondents
(N = 85)
p
Survey question: Of the SRMs that were treated, what percentage of cases were treated by…
Open partial nephrectomy <0.001
0% 40.3 22.1
10% 50.6 41.6
≥25% 9.1 36.4
Open radical nephrectomy 0.039
0% 44.2 31.2
10% 46.8 55.8
≥25% 9.1 13.0
Laparoscopic partial
nephrectomy
0.002
0% 84.4 63.6
10% 6.5 19.5
≥25% 9.1 16.9
Laparoscopic radical
nephrectomy
0.041
0% 26.0 18.2
10% 32.5 23.4
≥25% 41.6 58.4
Robotic partial nephrectomy <0.001
≤10% 10.4 36.4
25% 23.4 27.3
50% 37.7 23.4
≥75% 28.6 13.0
Robotic radical nephrectomy 0.031
0% 61.0 72.7
10% 19.5 16.9
≥25% 19.5 10.4
Percutaneous ablation 0.865
0% 31.2 32.5
10% 50.6 53.2
≥25% 18.2 14.3
Laparoscopic ablation 0.001
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By residency time frame
Urologists who completed residency at least 15 years ago had
greater utilization of laparoscopic partial nephrectomy over
the last year compared to those who completed residency
more recently (p = 0.002). Otherwise, the data yielded similar
utilization of the different treatment modalities both in the
past year and 5 years prior (Supplementary Table 5a and 5b).
Discussion
While open radical nephrectomy was formerly the standard
of care (15), there now exist several effective options for mana-
ging SRMs. These include open or minimally invasive radical
or partial nephrectomy, percutaneous cryo-, microwave, or
radiofrequency ablation, and active surveillance (8). Many
of these treatment modalities have only recently gained popu-
larity, as they involve newer technologies and practices. This
study explored the differences in utilization of these modalities
in the past year and 5 years prior among members of
the Endourological Society within the United States. Survey
data demonstrated increasing usage of robotic partial and
radical nephrectomy (p < 0.001 and p = 0.031, respectively)
and microwave ablation (p = 0.008), and decreasing usage
of other surgical treatments (p values < 0.05), radiofrequency
ablation (p = 0.002), and laparoscopic ablation (p = 0.001).
Urologists trended toward increasing utilization of
robotic partial and radical nephrectomy over the past 5
years (p < 0.001 and p = 0.031, respectively). In contrast,
there was decreasing utilization of open partial nephrectomy
(p < 0.001), open radical nephrectomy (p = 0.039), laparo-
scopic partial nephrectomy (p = 0.002), and laparoscopic
radical nephrectomy (p = 0.041). These changes reﬂect the
growing usage of robotic surgery in the management of
SRMs (16, 17). Recent studies have suggested an underutiliza-
tion of partial nephrectomy in general, but the availability
of robotic technology facilitates an increase in the rate of
partial nephrectomy (10–13). On a population level, Patel
et al. showed that patients are more likely to undergo a partial
nephrectomy if their urologist performs robotic surgery (17).
There are well-described advantages of robotic partial
nephrectomy compared with laparoscopic surgery; therefore,
further displacement of laparoscopic partial nephrectomy
would be appropriate. One large meta-analysis showed robotic
partial nephrectomy to have shorter, warm ischemia time,
shorter hospital stays, and lower rates of conversion to open
surgery (18). Subjectively, robotic surgery allows for more pre-
cise surgical maneuvers and offers a relatively short learning
curve compared with the laparoscopic approach (19, 20).
The diffusion of technology in urologic surgery has garnered
debate in recent years. Although the adoption of new surgical
techniques and platforms (i.e., robotic surgery) is paramount
to continued innovation and improved patient outcomes,
many have aptly argued that more fastidious research and eva-
luation of new technology is prudent. The widespread adoption
of robotic partial nephrectomy, for example, has afforded a
minimally invasive and nephron-sparing approach to many
Table 3. (Continued )
Usage rate per modality
Within the past year
Percentage of respondents
(N = 124)
Five years ago
Percentage of respondents
(N = 85)
p
0% 81.8 63.4
≥10% 18.2 36.4
Survey question: Of the SRMs that were treated with image-guided ablation, what percentage of cases were treated by…
Cryoablation 0.362
0%–10% 15.7 19.6
25%–75% 29.4 23.5
90%–100% 54.9 56.9
Radiofrequency ablation 0.002
0% 60.8 45.1
10%–50% 25.5 39.2
75%–100% 13.7 15.7
Microwave ablation 0.008
0% 76.5 94.1
≥10% 23.5 5.9
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Table 4. Abridged summary of respondent practice patterns for SRMs within the past 5 years
Variable
Within the past year
Respondents (%) (N = 124)
Five years ago
Respondents (%) (N = 87)
Number of renal masses
<5 6 (4.8) 4 (4.6)
5–10 10 (8.1) 6 (6.9)
11–20 20 (16.1) 11 (12.6)
21–30 15 (12.1) 17 (19.5)
31–40 22 (17.7) 14 (16.1)
>40 51 (41.1) 35 (40.2)
Unavailable treatment options
Robotic surgery 5 (4.0) 14 (16.5)
Laparoscopic surgery 5 (4.0) 3 (3.5)
Percutaneous ablation 11 (8.9) 10 (11.8)
Laparoscopic ablation 26 (21.0) 15 (17.6)
All available 92 (74.2) 56 (65.9)
Active surveillance, percent
0 3 (2.4) 6 (7.2)
10 65 (52.4) 51 (61.4)
25 43 (34.7) 23 (27.7)
≥50 13 (10.5) 3 (3.6)
Open partial nephrectomy, percent
0 49 (42.2) 17 (21.3)
10 55 (47.4) 34 (42.5)
25 7 (6.0) 22 (27.5)
≥50 5 (4.3) 7 (8.8)
Open radical nephrectomy, percent
0 59 (50.9) 24 (30.0)
10 46 (39.7) 46 (57.5)
25 10 (8.6) 8 (10.0)
≥50 1 (0.9) 2 (2.5)
Laparoscopic partial nephrectomy, percent
0 96 (82.8) 51 (63.8)
10 8 (6.9) 16 (20.0)
25 7 (6.0) 8 (10.0)
≥50 5 (4.3) 5 (6.3)
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patients who may have otherwise undergone radical nephrect-
omy (12, 21). The potential beneﬁts of partial nephrectomy
and, speciﬁcally, minimally invasive partial nephrectomy are
well established (22–28). In fact, it has recently been proposed
that robotic partial nephrectomy is becoming the standard
of care for SRMs. Previously, authors have argued that diffu-
sion of minimally invasive and nephron-sparing surgery was,
in fact, too hindered and dependent on surgeon preference,
especially given its purported safety (16, 29, 30). Conversely,
others have pronounced the process of robotic adoption as
hurried and dubious, with little oversight or prospective rando-
mized data to support its utilization. Comparative concerns
may be drawn from the rapid dissemination of robotic prosta-
tectomy. Parsons et al. demonstrated that during the early
adoption of robotic prostatectomy, there was increased risk
of patient safety indicators (adjusted odds ratio, 2.0; 95%
CI, 1.1–3.7; p = 0.02) (31). Of course, large prospective ran-
domized trials are costly, time-consuming, and onerous.
Hence, the debate regarding the optimal evaluation and
institution of new technology continues. From the present
data, it certainly appears that the diffusion process has
been signiﬁcant over the last 5 years for both robotic partial
nephrectomy (p < 0.001) and the newest form of percuta-
neous ablation—microwave (p = 0.008).
Table 4. (Continued )
Variable
Within the past year
Respondents (%) (N = 124)
Five years ago
Respondents (%) (N = 87)
Laparoscopic radical nephrectomy, percent
0 30 (25.9) 14 (17.5)
10 40 (34.5) 18 (22.5)
25 38 (32.8) 36 (45.0)
≥50 8 (6.9) 12 (15.0)
Robotic partial nephrectomy, percent
0 10 (8.6) 20 (25.0)
10 5 (4.3) 8 (10.0)
25 25 (21.6) 22 (27.5)
≥50 76 (65.5) 30 (37.5)
Robotic radical nephrectomy, percent
0 72 (62.1) 58 (72.5)
10 23 (19.8) 14 (17.5)
25 15 (12.9) 6 (7.5)
≥50 6 (5.2) 2 (2.5)
Percutaneous ablation, percent
0 37 (31.9) 27 (33.8)
10 61 (52.6) 42 (52.5)
25 18 (15.5) 10 (12.5)
≥50 0 (0.0) 1 (1.3)
Laparoscopic ablation, percent
0 100 (86.2) 50 (62.5)
10 14 (12.1) 23 (28.8)
25 2 (1.7) 6 (7.5)
≥50 0 (0.0) 1 (1.3)
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As urologic surgery continues to trend toward minimally
invasive interventions, there has been heightened reliance
on image guidance. Although open surgery remains a trusted
and effective approach for the management of SRMs, the
evolution of laparoscopic extirpation and ablation to robotic
enucleation and percutaneous ablation has been demonstrative.
Appropriately, the collaboration of urologists and radiologists
is critical. The intraoperative interpretation of robotically con-
trolled ultrasound is something with which many urologists
have become comfortable. However, a cooperative partnership
with radiologists affords the urologist the opportunity to have
a “second opinion” intraoperatively for challenging cases.
Furthermore, although percutaneous ablation, and particularly
microwave ablation, has been championed by radiologists at
many institutions, the urologist’s role remains vital in several
ways. The identiﬁcation of potential candidates for ablation is
augmented by consultation with radiology. Moreland et al.
described the experience of having both a urologist and a
radiologist in the procedure suite for ablative cases (32).
Furthermore, Welch et al. postulated that this relationship,
commensurate with a higher volume of procedures, improves
patient safety (33). The present survey illustrates that with this
partnership and the appropriate diffusion of new research,
radiofrequency utilization has decreased (Table 3, p = 0.02),
while employment of cryoablation has remained steady (Table
3, p = 0.362), and usage of microwave ablation has increased
(Table 3, p = 0.008). Emerging evidence conveys the inferiority
of radiofrequency ablation relative to cryoablation (34, 35).
Finally, the increased utilization of microwave ablation over
the last 5 years and its postulated advantages (36) are likely
the product of this productive, concerted relationship.
When comparing percutaneous ablation to laparoscopic
ablation, survey data showed that usage of percutaneous
ablation has remained relatively constant (p = 0.865), while
the usage of laparoscopic ablation has decreased in recent
years (p = 0.001). Theoretical advantages of the laparoscopic
approach include placement of probes under direct visualiza-
tion and treatment of anterior tumors. Beneﬁts of the
percutaneous approach include the avoidance of a general
anesthetic, shorter recovery time, and the ability to perform
the procedure on an outpatient basis. Given the similar
oncologic and functional outcomes between laparoscopic
and percutaneous ablation demonstrated by Zargar et al.
(37), it is understandable that laparoscopic ablation has
fallen out of favor over the past 5 years.
There are a few important limitations of this study.
First, the low survey response rate may have biased results.
Additionally, only surveying members of the Endourological
Society likely resulted in a higher rate of respondents who
were endourology trained. Because respondents were asked
to remember their practice patterns retrospectively, recall
bias may have also affected the data. Finally, although survey
data allowed for associations to be made between practice
patterns and provider characteristics, no conclusions could
be drawn on why those associations exist.
Conclusion
The availability and utilization of robotic surgery have
increased over the last 5 years, whereas utilization of open
and laparoscopic surgery has decreased. The employment of
percutaneous ablation has remained the same, whereas that of
laparoscopic ablation has decreased. Although all of these are
acceptable treatment modalities for SRMs per the AUA guide-
lines, the authors hope that examining usage patterns and trends
will spur discussion on the most effective treatment modalities
based on provider, patient, and tumor characteristics.
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